WO2009041062A1 - 血漿中動態が改善されたグリピカン3抗体 - Google Patents
血漿中動態が改善されたグリピカン3抗体 Download PDFInfo
- Publication number
- WO2009041062A1 WO2009041062A1 PCT/JP2008/002690 JP2008002690W WO2009041062A1 WO 2009041062 A1 WO2009041062 A1 WO 2009041062A1 JP 2008002690 W JP2008002690 W JP 2008002690W WO 2009041062 A1 WO2009041062 A1 WO 2009041062A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- glypican
- plasma
- life
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
- C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (42)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2700986A CA2700986A1 (en) | 2007-09-28 | 2008-09-26 | Anti-glypican-3 antibody having improved kinetics in plasma |
BRPI0817637A BRPI0817637A2 (pt) | 2007-09-28 | 2008-09-26 | anticorpo anti-glipican-3 tendo cinéticas aperfeiçoadas no plasma |
DK08834671.3T DK2196541T3 (da) | 2007-09-28 | 2008-09-26 | Anti-glypican-3-antistof med forbedret kinetik i plasmaet |
MX2010003158A MX2010003158A (es) | 2007-09-28 | 2008-09-26 | Anticuerpo anti-glipicano-3 que tiene cinetica mejorada en plasma. |
ES08834671T ES2394471T3 (es) | 2007-09-28 | 2008-09-26 | Anticuerpo Anti-Glipicano 3 que tiene una cinética mejorada en plasma |
JP2009534190A JP4535406B2 (ja) | 2007-09-28 | 2008-09-26 | 血漿中動態が改善されたグリピカン3抗体 |
CN2008801091960A CN101809162B (zh) | 2007-09-28 | 2008-09-26 | 血浆中动力学被改善的磷脂酰肌醇蛋白聚糖3抗体 |
EP08834671A EP2196541B1 (en) | 2007-09-28 | 2008-09-26 | Anti-glypican-3 antibody having improved kinetics in plasma |
KR1020157030933A KR20150126724A (ko) | 2007-09-28 | 2008-09-26 | 혈장 중 반응속도가 개선된 항-글리피칸-3 항체 |
AU2008305851A AU2008305851B2 (en) | 2007-09-28 | 2008-09-26 | Anti-glypican-3 antibody having improved kinetics in plasma |
US12/733,933 US8497355B2 (en) | 2007-09-28 | 2008-09-26 | Anti-glypican-3 antibody having improved kinetics in plasma |
NZ584769A NZ584769A (en) | 2007-09-28 | 2008-09-26 | Anti-glypican-3 antibody having improved kinetics in plasma |
CL2009000647A CL2009000647A1 (es) | 2008-04-04 | 2009-03-18 | Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto. |
EP09727052A EP2275135A4 (en) | 2008-04-04 | 2009-03-19 | THERAPY FOR HEPATIC CANCER |
PE2009000413A PE20091655A1 (es) | 2008-04-04 | 2009-03-19 | Farmaco para el cancer de higado |
CN200980119069.3A CN102046200B (zh) | 2008-04-04 | 2009-03-19 | 肝癌治疗剂 |
ARP090100996A AR071003A1 (es) | 2008-04-04 | 2009-03-19 | Farmaco contra cancer de higado |
UAA201013035A UA103614C2 (uk) | 2008-04-04 | 2009-03-19 | Лікарський засіб, що містить комбінацію інгібітора кінази та анти-гліпікан 3-антитіла, для лікування раку печінки |
PCT/JP2009/001249 WO2009122667A1 (ja) | 2008-04-04 | 2009-03-19 | 肝癌治療剤 |
BRPI0911147A BRPI0911147A2 (pt) | 2008-04-04 | 2009-03-19 | fármaco contra câncer de fígado |
TW98108942A TWI468175B (zh) | 2008-04-04 | 2009-03-19 | Liver cancer treatment |
CA2720359A CA2720359A1 (en) | 2008-04-04 | 2009-03-19 | Liver cancer drug |
SG2013025549A SG189754A1 (en) | 2008-04-04 | 2009-03-19 | Liver cancer drug |
KR1020107024691A KR101612139B1 (ko) | 2008-04-04 | 2009-03-19 | 간암 치료제 |
AU2009233301A AU2009233301B2 (en) | 2008-04-04 | 2009-03-19 | Liver cancer drug |
JP2010505322A JP5306327B2 (ja) | 2008-04-04 | 2009-03-19 | 肝癌治療剤 |
MX2010010954A MX2010010954A (es) | 2008-04-04 | 2009-03-19 | Farmaco contra cancer de higado. |
NZ588913A NZ588913A (en) | 2008-04-04 | 2009-03-19 | Liver cancer drug |
RU2010145177/15A RU2523897C2 (ru) | 2008-04-04 | 2009-03-19 | Лекарственное средство для лечения рака печени |
IL204754A IL204754A0 (en) | 2007-09-28 | 2010-03-25 | Anti-glypican - 3 - antibody having improved kinetics in plasma |
MA32777A MA31780B1 (fr) | 2007-09-28 | 2010-04-14 | Anticorps anti-glypican-3 dont la cinétique dans le plasma est améliorée |
ZA2010/02741A ZA201002741B (en) | 2007-09-28 | 2010-04-19 | Anti-glypican-3 antibody having improved kinetics in plasma |
IL208451A IL208451A0 (en) | 2008-04-04 | 2010-10-03 | Pharmaceutical compositions comprising a chemotherapeutic agent and an anti-glypican 3 antibody for use in treating hepatic cancer |
CO10133385A CO6300964A2 (es) | 2008-04-04 | 2010-10-27 | Una composicion farmaceutica que comprende una combinacion de un agente quimioterapeutico y un anticuerpo 3 antiglipicano |
CR11769A CR11769A (es) | 2008-04-04 | 2010-11-01 | Farmaco contra el cancer de higado |
MA33323A MA32360B1 (fr) | 2008-04-04 | 2010-11-03 | Thérapie pour cancer hépatique |
EC2010010589A ECSP10010589A (es) | 2008-04-04 | 2010-11-04 | Farmaco contra el cancer de higado |
HK10111189.6A HK1144702A1 (en) | 2007-09-28 | 2010-12-01 | Anti-glypican-3 antibody having improved kinetics in plasma |
JP2010291590A JP5506654B2 (ja) | 2008-04-04 | 2010-12-28 | 肝癌治療剤 |
HK11105940.7A HK1151734A1 (en) | 2008-04-04 | 2011-06-13 | Therapeutic for hepatic cancer |
US13/924,957 US20130295612A1 (en) | 2007-09-28 | 2013-07-25 | Anti-glypican-3 antibody having improved kinetics in plasma |
US14/629,967 US20150315278A1 (en) | 2007-09-28 | 2015-02-24 | Anti-Glypican-3 Antibody Having Improved Kinetics in Plasma |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007-256063 | 2007-09-28 | ||
JP2007256063 | 2007-09-28 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/733,933 A-371-Of-International US8497355B2 (en) | 2007-09-28 | 2008-09-26 | Anti-glypican-3 antibody having improved kinetics in plasma |
US13/924,957 Division US20130295612A1 (en) | 2007-09-28 | 2013-07-25 | Anti-glypican-3 antibody having improved kinetics in plasma |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009041062A1 true WO2009041062A1 (ja) | 2009-04-02 |
Family
ID=40510966
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/002690 WO2009041062A1 (ja) | 2007-09-28 | 2008-09-26 | 血漿中動態が改善されたグリピカン3抗体 |
Country Status (26)
Country | Link |
---|---|
US (3) | US8497355B2 (ja) |
EP (3) | EP2196541B1 (ja) |
JP (3) | JP4535406B2 (ja) |
KR (2) | KR20150126724A (ja) |
CN (1) | CN101809162B (ja) |
AR (1) | AR066172A1 (ja) |
AU (1) | AU2008305851B2 (ja) |
BR (1) | BRPI0817637A2 (ja) |
CA (1) | CA2700986A1 (ja) |
CL (1) | CL2008002873A1 (ja) |
CO (1) | CO6270266A2 (ja) |
CR (1) | CR11369A (ja) |
DK (1) | DK2196541T3 (ja) |
EC (1) | ECSP10010135A (ja) |
ES (1) | ES2394471T3 (ja) |
HK (1) | HK1144702A1 (ja) |
IL (1) | IL204754A0 (ja) |
MA (1) | MA31780B1 (ja) |
MX (1) | MX2010003158A (ja) |
MY (1) | MY148637A (ja) |
NZ (1) | NZ584769A (ja) |
PE (1) | PE20091218A1 (ja) |
RU (2) | RU2445366C2 (ja) |
TW (1) | TWI418363B (ja) |
WO (1) | WO2009041062A1 (ja) |
ZA (1) | ZA201002741B (ja) |
Cited By (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009077569A1 (en) * | 2007-12-19 | 2009-06-25 | General Electric Company | Biokinetics of fast-clearing polypeptides |
US20110104157A1 (en) * | 2008-04-04 | 2011-05-05 | Chugai Seiyaku Kabushiki Kaisha | Liver cancer drug |
US8124725B2 (en) | 2007-12-19 | 2012-02-28 | General Electric Company | PDGF-Rβ binders |
WO2012115241A1 (ja) | 2011-02-25 | 2012-08-30 | 中外製薬株式会社 | FcγRIIb特異的Fc抗体 |
WO2012133782A1 (ja) | 2011-03-30 | 2012-10-04 | 中外製薬株式会社 | 抗原結合分子の血漿中滞留性と免疫原性を改変する方法 |
WO2013002362A1 (ja) | 2011-06-30 | 2013-01-03 | 中外製薬株式会社 | ヘテロ二量化ポリペプチド |
JPWO2011108714A1 (ja) * | 2010-03-04 | 2013-06-27 | 中外製薬株式会社 | 抗体定常領域改変体 |
WO2013100120A1 (ja) | 2011-12-28 | 2013-07-04 | 中外製薬株式会社 | ヒト化抗Epiregulin抗体および当該抗体を有効成分として含む癌治療剤 |
JP2013539361A (ja) * | 2010-07-29 | 2013-10-24 | ゼンコア インコーポレイテッド | 改変された等電点を有する抗体 |
WO2013187495A1 (ja) | 2012-06-14 | 2013-12-19 | 中外製薬株式会社 | 改変されたFc領域を含む抗原結合分子 |
KR20140015501A (ko) * | 2011-03-30 | 2014-02-06 | 추가이 세이야쿠 가부시키가이샤 | 항원 결합 분자의 혈장 체류성과 면역원성을 개변하는 방법 |
WO2014030728A1 (ja) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | FcγRIIb特異的Fc領域改変体 |
JPWO2012073992A1 (ja) * | 2010-11-30 | 2014-05-19 | 中外製薬株式会社 | 複数分子の抗原に繰り返し結合する抗原結合分子 |
WO2014097648A1 (ja) | 2012-12-21 | 2014-06-26 | 中外製薬株式会社 | Gpc3標的治療剤療法が有効である患者に投与されるgpc3標的治療剤 |
WO2014104165A1 (ja) | 2012-12-27 | 2014-07-03 | 中外製薬株式会社 | ヘテロ二量化ポリペプチド |
WO2014208482A1 (ja) | 2013-06-24 | 2014-12-31 | 中外製薬株式会社 | ヒト化抗Epiregulin抗体を有効成分として含む腺癌以外の非小細胞肺癌の治療剤 |
US9228017B2 (en) | 2009-03-19 | 2016-01-05 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
WO2016098357A1 (en) | 2014-12-19 | 2016-06-23 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
KR20170003972A (ko) | 2014-05-08 | 2017-01-10 | 추가이 세이야쿠 가부시키가이샤 | Gpc3 표적 치료제 요법이 유효한 환자에게 투여되는 gpc3 표적 치료제 |
US9670269B2 (en) | 2006-03-31 | 2017-06-06 | Chugai Seiyaku Kabushiki Kaisha | Methods of modifying antibodies for purification of bispecific antibodies |
US9688762B2 (en) | 2007-09-26 | 2017-06-27 | Chugai Sciyaku Kabushiki Kaisha | Modified antibody constant region |
US9765135B2 (en) | 2014-12-19 | 2017-09-19 | Chugai Seiyaku Kabushiki Kaisha | Anti-C5 antibodies |
WO2017159699A1 (en) | 2016-03-15 | 2017-09-21 | Chugai Seiyaku Kabushiki Kaisha | Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies |
US9828429B2 (en) | 2007-09-26 | 2017-11-28 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
US9868948B2 (en) | 2008-04-11 | 2018-01-16 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
EP2467400B1 (en) | 2009-08-21 | 2018-01-24 | Lonza Biologics plc. | Variant immunoglobulins with improved manufacturability |
WO2018038046A1 (ja) | 2016-08-22 | 2018-03-01 | 中外製薬株式会社 | ヒトgpc3ポリペプチドを発現する遺伝子改変非ヒト動物 |
US9969800B2 (en) | 2015-02-05 | 2018-05-15 | Chugai Seiyaku Kabushiki Kaisha | IL-8 antibodies |
US9975966B2 (en) | 2014-09-26 | 2018-05-22 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing theraputic agent |
US10011858B2 (en) | 2005-03-31 | 2018-07-03 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
WO2018155611A1 (ja) | 2017-02-24 | 2018-08-30 | 中外製薬株式会社 | 薬学的組成物、抗原結合分子、治療方法、およびスクリーニング方法 |
US10118959B2 (en) | 2005-10-14 | 2018-11-06 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican-3 antibody |
US10150808B2 (en) | 2009-09-24 | 2018-12-11 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant regions |
WO2019059411A1 (en) | 2017-09-20 | 2019-03-28 | Chugai Seiyaku Kabushiki Kaisha | DOSAGE FOR POLYTHERAPY USING PD-1 AXIS BINDING ANTAGONISTS AND GPC3 TARGETING AGENT |
US10253091B2 (en) | 2009-03-19 | 2019-04-09 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
US10253100B2 (en) | 2011-09-30 | 2019-04-09 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance |
EP3557260A1 (en) | 2012-12-21 | 2019-10-23 | Chugai Seiyaku Kabushiki Kaisha | Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy |
US10662245B2 (en) | 2008-09-26 | 2020-05-26 | Chugai Seiyaku Kabushiki Kaisha | Methods of reducing IL-6 activity for disease treatment |
US10774148B2 (en) | 2015-02-27 | 2020-09-15 | Chugai Seiyaku Kabushiki Kaisha | Composition for treating IL-6-related diseases |
KR20200121900A (ko) * | 2011-03-30 | 2020-10-26 | 추가이 세이야쿠 가부시키가이샤 | 항원 결합 분자의 혈장 체류성과 면역원성을 개변하는 방법 |
US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
US11053308B2 (en) | 2016-08-05 | 2021-07-06 | Chugai Seiyaku Kabushiki Kaisha | Method for treating IL-8-related diseases |
US11124576B2 (en) | 2013-09-27 | 2021-09-21 | Chungai Seiyaku Kabushiki Kaisha | Method for producing polypeptide heteromultimer |
US11142587B2 (en) | 2015-04-01 | 2021-10-12 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide hetero-oligomer |
US11267868B2 (en) | 2013-04-02 | 2022-03-08 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
US11352440B2 (en) | 2014-11-21 | 2022-06-07 | Bristol-Myers Squibb Company | Antibodies against CD73 and uses thereof |
US11359009B2 (en) | 2015-12-25 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
US11376326B2 (en) | 2015-07-01 | 2022-07-05 | Chugai Seiyaku Kabushiki Kaisha | GPC3-targeting therapeutic agent which is administered to patient for whom the GPC3-targeting therapeutic agent is effective |
US11608374B2 (en) | 2017-01-30 | 2023-03-21 | Chugai Seiyaku Kabushiki Kaisha | Anti-sclerostin antibodies and methods of use |
US11649262B2 (en) | 2015-12-28 | 2023-05-16 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of Fc region-containing polypeptide |
WO2023091909A1 (en) | 2021-11-16 | 2023-05-25 | Sotio Biotech Inc. | Treatment of myxoid/round cell liposarcoma patients |
US11820793B2 (en) | 2011-11-30 | 2023-11-21 | Chugai Seiyaku Kabushiki Kaisha | Drug containing carrier into cell for forming immune complex |
US11827699B2 (en) | 2011-09-30 | 2023-11-28 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing antibodies promoting disappearance of antigens having plurality of biological activities |
US11851486B2 (en) | 2017-05-02 | 2023-12-26 | National Center Of Neurology And Psychiatry | Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils |
WO2024038144A1 (en) | 2022-08-18 | 2024-02-22 | Tribune Therapeutics Ab | Agents that inhibit ccn ligand-induced signalling for treating disease |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0821110B8 (pt) * | 2007-12-05 | 2021-05-25 | Chugai Pharmaceutical Co Ltd | anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo |
MA33405B1 (fr) | 2009-05-15 | 2012-07-03 | Chugai Pharmaceutical Co Ltd | Anticorps anti-axl |
SA111320266B1 (ar) * | 2010-03-11 | 2015-06-21 | رينات نيوروساينس كوربوريشن | أجسام مضادة مع ارتباط مولد مضاد يعتمد على الأس الهيدروجيني |
TR201802772T4 (tr) | 2010-11-17 | 2018-03-21 | Chugai Pharmaceutical Co Ltd | Kan pıhtılaşma faktörü VIII in işlevi için alternatif işleve sahip multi-spesifik antijen bağlayıcı molekül. |
SG10202102283TA (en) | 2011-09-30 | 2021-04-29 | Chugai Pharmaceutical Co Ltd | Ion concentration-dependent binding molecule library |
WO2013181543A1 (en) * | 2012-06-01 | 2013-12-05 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | High-affinity monoclonal antibodies to glypican-3 and use thereof |
IN2014DN11157A (ja) | 2012-07-13 | 2015-10-02 | Roche Glycart Ag | |
CN111402950B (zh) | 2013-11-29 | 2024-03-19 | 豪夫迈·罗氏有限公司 | 抗体选择装置和方法 |
US9926377B2 (en) | 2014-05-22 | 2018-03-27 | Genentech, Inc. | Anti-GPC3 antibodies and immunoconjugates |
BR112016027222A2 (pt) * | 2014-05-22 | 2018-01-30 | Genentech Inc | anticorpos isolados, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de tratamento de um indivíduo com um câncer, de inibição da proliferação de uma célula, de detecção de gpc3 humano e de detecção de um câncer |
US10093746B2 (en) | 2014-09-04 | 2018-10-09 | The Trustees Of The University Of Pennsylvania | Glypican-3 antibody and uses thereof |
CN107208025A (zh) | 2014-11-25 | 2017-09-26 | 康宁股份有限公司 | 延续细胞培养基的材料和方法 |
AU2017233658B2 (en) | 2016-03-14 | 2023-09-21 | Chugai Seiyaku Kabushiki Kaisha | Cell injury inducing therapeutic drug for use in cancer therapy |
CN105820250B (zh) * | 2016-04-29 | 2019-04-30 | 中国人民解放军第四军医大学 | 一种抗basigin人源化抗体及其应用 |
BR112019011186A2 (pt) | 2016-12-01 | 2019-10-08 | Regeneron Pharma | conjugado de anticorpo radiomarcado, composto, e, métodos de imageamento e para tratamento de um tumor. |
WO2021236546A1 (en) * | 2020-05-18 | 2021-11-25 | Bristol-Myers Squibb Company | Antibody variants with improved pharmacokinetic properties |
CA3186914A1 (en) | 2020-07-28 | 2022-02-03 | Masakazu Fukuda | Prefilled syringe formulation with needle with needle shield containing novel modified antibody |
CN117897410A (zh) * | 2021-09-06 | 2024-04-16 | 南京传奇生物科技有限公司 | 抗gpc3嵌合抗原受体及其使用方法 |
WO2024011186A2 (en) * | 2022-07-08 | 2024-01-11 | Imaginab, Inc. | Antibodies and methods of making and using same |
Citations (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0125023A1 (en) | 1983-04-08 | 1984-11-14 | Genentech, Inc. | Recombinant immunoglobulin preparations, methods for their preparation, DNA sequences, expression vectors and recombinant host cells therefor |
EP0239400A2 (en) | 1986-03-27 | 1987-09-30 | Medical Research Council | Recombinant antibodies and methods for their production |
JPS6459878A (en) | 1987-08-31 | 1989-03-07 | Matsushita Electric Ind Co Ltd | Semiconductor laser protective circuit |
JPH0228200A (ja) * | 1988-02-17 | 1990-01-30 | Neorx Corp | 電荷調整によるタンパク質の薬物動力学の変更 |
WO1992001047A1 (en) | 1990-07-10 | 1992-01-23 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1993006213A1 (en) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1993019172A1 (en) | 1992-03-24 | 1993-09-30 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
WO1995001438A1 (en) | 1993-06-30 | 1995-01-12 | Medical Research Council | Sbp members with a chemical moiety covalently bound within the binding site; production and selection thereof |
WO1995015388A1 (en) | 1993-12-03 | 1995-06-08 | Medical Research Council | Recombinant binding proteins and peptides |
WO1995015393A1 (fr) | 1993-12-03 | 1995-06-08 | Asahi Kasei Kogyo Kabushiki Kaisha | Nouveau vecteur de detection d'expression |
WO1996002576A1 (fr) | 1994-07-13 | 1996-02-01 | Chugai Seiyaku Kabushiki Kaisha | Anticorps humain reconstitue contre l'interleukine-8 humaine |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1998013388A1 (fr) | 1996-09-26 | 1998-04-02 | Chugai Seiyaku Kabushiki Kaisha | Anticorps contre les peptides lies a la parathormone humaine |
WO1998046777A1 (fr) | 1997-04-11 | 1998-10-22 | Centre National De La Recherche Scientifique (Cnrs) | Preparation de recepteurs membranaires a partir de baculovirus extracellulaires |
WO1999018212A1 (fr) | 1997-10-03 | 1999-04-15 | Chugai Seiyaku Kabushiki Kaisha | Anticorps humain naturel |
WO2003000883A1 (en) | 2001-06-22 | 2003-01-03 | Chugai Seiyaku Kabushiki Kaisha | Cell proliferation inhibitors containing anti-glypican 3 antibody |
WO2006046751A1 (ja) | 2004-10-26 | 2006-05-04 | Chugai Seiyaku Kabushiki Kaisha | 糖鎖改変抗グリピカン3抗体 |
WO2006067913A1 (ja) | 2004-12-22 | 2006-06-29 | Chugai Seiyaku Kabushiki Kaisha | フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法 |
WO2007005612A2 (en) * | 2005-07-01 | 2007-01-11 | Medimmune, Inc. | An integrated approach for generating multidomain protein therapeutics |
JP2007256063A (ja) | 2006-03-23 | 2007-10-04 | Seiko Epson Corp | 表示装置、および、電子機器 |
JP2008504970A (ja) | 2004-07-06 | 2008-02-21 | エス・エム・エス・デマーク・アクチエンゲゼルシャフト | 多段圧延スタンド、特に20ロール送り圧延機構において冷間圧延の特殊鋼ストリップ或いは特殊鋼箔の平坦度及びストリップ応力又はそのいずれかの一方を測定制御する方法と装置 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2259163C (en) * | 1996-07-19 | 2004-07-06 | Amgen Inc. | Nt-3 and bdnf analogs having improved circulating life and/or absorption |
DK1914244T3 (da) * | 1999-04-09 | 2013-07-22 | Kyowa Hakko Kirin Co Ltd | Fremgangsmåde til at modulere aktiviteten af funktionelle immunmolekyler. |
GB0017635D0 (en) | 2000-07-18 | 2000-09-06 | Pharmacia & Upjohn Spa | Antitumor combined therapy |
US7317091B2 (en) * | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US20060088899A1 (en) * | 2002-05-31 | 2006-04-27 | Alvarez Vernon L | Combination chemotherapy with chlorotoxin |
WO2004023145A1 (ja) * | 2002-09-04 | 2004-03-18 | Perseus Proteomics Inc. | Gpc3の検出による癌の診断方法 |
DK2364996T3 (en) * | 2002-09-27 | 2017-02-06 | Xencor Inc | Optimized Fc variants and methods for their formation |
SI1562972T1 (sl) | 2002-10-15 | 2010-12-31 | Facet Biotech Corp | ALTERACIJA FcRn VEZANIH AFINITET ALI SERUMSKIH RAZPOLOVNIH DOB ANTITELESC Z MUTAGENEZO |
US7217797B2 (en) * | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
JP2008501677A (ja) | 2004-06-04 | 2008-01-24 | ファイザー・プロダクツ・インク | 異常な細胞増殖を治療する方法 |
KR101300545B1 (ko) * | 2004-07-09 | 2013-09-02 | 츄가이 세이야꾸 가부시키가이샤 | 항 글리피칸 3 항체 |
EP1800693B1 (en) | 2004-08-24 | 2013-07-17 | Chugai Seiyaku Kabushiki Kaisha | Adjuvant therapy with the use of anti-glypican 3 antibody |
JP4455236B2 (ja) * | 2004-09-02 | 2010-04-21 | 本田技研工業株式会社 | 芝刈機 |
US20070087005A1 (en) * | 2005-10-14 | 2007-04-19 | Lazar Gregory A | Anti-glypican-3 antibody |
CA2627873A1 (en) | 2005-10-31 | 2007-05-10 | Scott Wilhelm | Treatment of cancer with sorafenib |
US20070185069A1 (en) * | 2005-11-14 | 2007-08-09 | Plum Stacy M | Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents |
WO2007059782A1 (en) * | 2005-11-28 | 2007-05-31 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
NZ570381A (en) | 2006-02-09 | 2011-02-25 | Daiichi Sankyo Co Ltd | Anti-cancer pharmaceutical composition |
WO2007099988A1 (ja) | 2006-02-28 | 2007-09-07 | Kyowa Hakko Kogyo Co., Ltd. | α-1,6-フコシルトランスフェラーゼ変異体とその用途 |
EP3345616A1 (en) * | 2006-03-31 | 2018-07-11 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
ES2568436T3 (es) | 2006-03-31 | 2016-04-29 | Chugai Seiyaku Kabushiki Kaisha | Procedimiento para controlar la farmacocinética en sangre de anticuerpos |
WO2007137170A2 (en) | 2006-05-20 | 2007-11-29 | Seattle Genetics, Inc. | Anti-glypican-3 antibody drug conjugates |
HUE028737T2 (en) * | 2007-07-17 | 2017-01-30 | Squibb & Sons Llc | Monoclonal antibodies to GLYPICAN-3 |
BRPI0817294A2 (pt) * | 2007-09-26 | 2015-03-17 | Chugai Pharmaceutical Co Ltd | Método de modificação do ponto isoelétrico de anticorpo via substituição de aminoácido em cdr. |
CL2009000647A1 (es) * | 2008-04-04 | 2010-06-04 | Chugai Pharmaceutical Co Ltd | Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto. |
-
2008
- 2008-09-26 US US12/733,933 patent/US8497355B2/en not_active Expired - Fee Related
- 2008-09-26 AU AU2008305851A patent/AU2008305851B2/en not_active Ceased
- 2008-09-26 MY MYPI2010001360A patent/MY148637A/en unknown
- 2008-09-26 BR BRPI0817637A patent/BRPI0817637A2/pt not_active IP Right Cessation
- 2008-09-26 MX MX2010003158A patent/MX2010003158A/es active IP Right Grant
- 2008-09-26 CA CA2700986A patent/CA2700986A1/en not_active Abandoned
- 2008-09-26 RU RU2010125605/10A patent/RU2445366C2/ru not_active IP Right Cessation
- 2008-09-26 EP EP08834671A patent/EP2196541B1/en not_active Not-in-force
- 2008-09-26 CN CN2008801091960A patent/CN101809162B/zh not_active Expired - Fee Related
- 2008-09-26 RU RU2010116756/10A patent/RU2010116756A/ru not_active Application Discontinuation
- 2008-09-26 JP JP2009534190A patent/JP4535406B2/ja not_active Expired - Fee Related
- 2008-09-26 ES ES08834671T patent/ES2394471T3/es active Active
- 2008-09-26 NZ NZ584769A patent/NZ584769A/en not_active IP Right Cessation
- 2008-09-26 EP EP12179554.6A patent/EP2584043A3/en not_active Ceased
- 2008-09-26 CL CL2008002873A patent/CL2008002873A1/es unknown
- 2008-09-26 AR ARP080104203A patent/AR066172A1/es not_active Application Discontinuation
- 2008-09-26 EP EP12179558.7A patent/EP2617736A1/en not_active Withdrawn
- 2008-09-26 WO PCT/JP2008/002690 patent/WO2009041062A1/ja active Application Filing
- 2008-09-26 TW TW097137297A patent/TWI418363B/zh not_active IP Right Cessation
- 2008-09-26 KR KR1020157030933A patent/KR20150126724A/ko not_active Application Discontinuation
- 2008-09-26 DK DK08834671.3T patent/DK2196541T3/da active
- 2008-09-26 KR KR1020107008895A patent/KR20100085067A/ko active IP Right Grant
- 2008-10-10 PE PE2008001682A patent/PE20091218A1/es not_active Application Discontinuation
-
2010
- 2010-03-25 IL IL204754A patent/IL204754A0/en unknown
- 2010-04-09 CO CO10041193A patent/CO6270266A2/es not_active Application Discontinuation
- 2010-04-14 MA MA32777A patent/MA31780B1/fr unknown
- 2010-04-14 CR CR11369A patent/CR11369A/es not_active Application Discontinuation
- 2010-04-19 ZA ZA2010/02741A patent/ZA201002741B/en unknown
- 2010-04-28 EC EC2010010137A patent/ECSP10010135A/es unknown
- 2010-06-10 JP JP2010132942A patent/JP5382873B2/ja not_active Expired - Fee Related
- 2010-12-01 HK HK10111189.6A patent/HK1144702A1/xx not_active IP Right Cessation
-
2013
- 2013-07-25 US US13/924,957 patent/US20130295612A1/en not_active Abandoned
- 2013-09-27 JP JP2013200716A patent/JP6101611B2/ja active Active
-
2015
- 2015-02-24 US US14/629,967 patent/US20150315278A1/en not_active Abandoned
Patent Citations (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0125023A1 (en) | 1983-04-08 | 1984-11-14 | Genentech, Inc. | Recombinant immunoglobulin preparations, methods for their preparation, DNA sequences, expression vectors and recombinant host cells therefor |
EP0239400A2 (en) | 1986-03-27 | 1987-09-30 | Medical Research Council | Recombinant antibodies and methods for their production |
EP0239400B1 (en) | 1986-03-27 | 1994-08-03 | Medical Research Council | Recombinant antibodies and methods for their production |
JPS6459878A (en) | 1987-08-31 | 1989-03-07 | Matsushita Electric Ind Co Ltd | Semiconductor laser protective circuit |
JPH0228200A (ja) * | 1988-02-17 | 1990-01-30 | Neorx Corp | 電荷調整によるタンパク質の薬物動力学の変更 |
WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1992001047A1 (en) | 1990-07-10 | 1992-01-23 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1993006213A1 (en) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1993019172A1 (en) | 1992-03-24 | 1993-09-30 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
WO1995001438A1 (en) | 1993-06-30 | 1995-01-12 | Medical Research Council | Sbp members with a chemical moiety covalently bound within the binding site; production and selection thereof |
WO1995015388A1 (en) | 1993-12-03 | 1995-06-08 | Medical Research Council | Recombinant binding proteins and peptides |
WO1995015393A1 (fr) | 1993-12-03 | 1995-06-08 | Asahi Kasei Kogyo Kabushiki Kaisha | Nouveau vecteur de detection d'expression |
WO1996002576A1 (fr) | 1994-07-13 | 1996-02-01 | Chugai Seiyaku Kabushiki Kaisha | Anticorps humain reconstitue contre l'interleukine-8 humaine |
WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1998013388A1 (fr) | 1996-09-26 | 1998-04-02 | Chugai Seiyaku Kabushiki Kaisha | Anticorps contre les peptides lies a la parathormone humaine |
WO1998046777A1 (fr) | 1997-04-11 | 1998-10-22 | Centre National De La Recherche Scientifique (Cnrs) | Preparation de recepteurs membranaires a partir de baculovirus extracellulaires |
WO1999018212A1 (fr) | 1997-10-03 | 1999-04-15 | Chugai Seiyaku Kabushiki Kaisha | Anticorps humain naturel |
WO2003000883A1 (en) | 2001-06-22 | 2003-01-03 | Chugai Seiyaku Kabushiki Kaisha | Cell proliferation inhibitors containing anti-glypican 3 antibody |
JP2008504970A (ja) | 2004-07-06 | 2008-02-21 | エス・エム・エス・デマーク・アクチエンゲゼルシャフト | 多段圧延スタンド、特に20ロール送り圧延機構において冷間圧延の特殊鋼ストリップ或いは特殊鋼箔の平坦度及びストリップ応力又はそのいずれかの一方を測定制御する方法と装置 |
WO2006046751A1 (ja) | 2004-10-26 | 2006-05-04 | Chugai Seiyaku Kabushiki Kaisha | 糖鎖改変抗グリピカン3抗体 |
WO2006067913A1 (ja) | 2004-12-22 | 2006-06-29 | Chugai Seiyaku Kabushiki Kaisha | フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法 |
WO2007005612A2 (en) * | 2005-07-01 | 2007-01-11 | Medimmune, Inc. | An integrated approach for generating multidomain protein therapeutics |
JP2007256063A (ja) | 2006-03-23 | 2007-10-04 | Seiko Epson Corp | 表示装置、および、電子機器 |
Non-Patent Citations (68)
Title |
---|
"A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY |
"Current Protocols in Immunology, Chapter 7, Immunologic studies in humans", 1993, JOHN WILEY & SONS, INC. |
"Current Protocols in Molecular Biology", 1987, JOHN WILEY & SONS, pages: 9.1 - 9.9 |
"Current Protocols in Molecular Biology", 1987, PUBLISH. JOHN WILEY & SONS, pages: 11.4 - 11.11 |
"Strategies for Protein Purification and Characterization: A Laboratory Course Manual", 1996, COLD SPRING HARBOR LABORATORY PRESS |
"These methods are described in a common textbook, Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY |
ABHINANDAN K. R.; MARTIN C. R., J. MOL. BIOL., vol. 369, 2007, pages 852 - 862 |
ADAMS C. W.; ALLISON D. E.; FLAGELLA K.; PRESTA L.; CLARKE J.; DYBDAL N.; MCKEEVER K.; SLIWKOWSKI M. X.: "Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab", CANCER IMMUNOL IMMUNOTHER, vol. 55, no. 6, 2006, pages 717 - 27 |
ALBINA NESTEROVA; PAUL J. CARTER; LEIA M. SMITH, GLYPICAN 3 AS A NOVEL TARGET FOR AN ANTIBODY-DRUG CONJUGATE, AACR ABSTRACT NO. 656, 4 April 2007 (2007-04-04) |
AMIT ET AL., SCIENCE, vol. 233, 1986, pages 747 - 53 |
BIGGE J. C. ET AL., ANALYTICAL BIOCHEMISTRY, vol. 230, no. 2, 1995, pages 229 - 238 |
BINZ H. K.; AMSTUTZ P.; PLUCKTHUN A.: "Engineering novel binding proteins from nonimmunoglobulin domains", NAT. BIOTECHNOL., vol. 23, no. 10, 2005, pages 1257 - 68 |
BIOTECHNOL. BIOENG., vol. 87, no. 5, 2004, pages 614 - 22 |
BIOTECHNOL. BIOENG., vol. 93, no. 5, 2006, pages 851 - 61 |
CHOTHIA ET AL., J. MOL. BIOL., vol. 196, 1987, pages 901 - 17 |
CHOTHIA ET AL., NATURE, vol. 342, 1989, pages 877 |
CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 8 |
COUTO J. R.; BLANK E. W.; PETERSON J. A.; CERIANI R. L.: "Anti-BA46 monoclonal antibody Mc3: humanization using a novel positional consensus and in vivo and in vitro characterization", CANCER RES., vol. 55, no. 8, 1995, pages 1717 - 22 |
COX K. M. ET AL., NAT. BIOTECHNOL., vol. 24, no. 12, 2006, pages 1591 - 7 |
DALL'ACQUA W. F.; DAMSCHRODER M. M.; ZHANG J.; WOODS R. M.; WIDJAJA L.; YU J.; WU H.: "Antibody humanization by framework shuffling", METHODS, vol. 36, no. 1, 2005, pages 43 - 60 |
EBERT ET AL., BIO/TECHNOLOGY, vol. 12, 1994, pages 699 - 702 |
EWERT S.; HONEGGER A.; PLUCKTHUN A.: "Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure- based framework engineering", METHODS, vol. 34, no. 2, 2004, pages 184 - 99 |
G. KOHLER; C. MILSTEIN, METHODS ENZYMOL., vol. 73, 1981, pages 3 - 46 |
GHETIE V.; POPOV S.; BORVAK J.; RADU C.; MATESOI D.; MEDESAN C.; OBER R. J.; WARD E. S.: "Increasing the serum persistence of an IgG fragment by random mutagenesis", NAT. BIOTECHNOL., vol. 15, no. 7, 1997, pages 637 - 40 |
GHETIE V.; POPOV S.; BORVAK J.; RADU C.; MATESOI D.; MEDESAN C.; OBER R. J; WARD E. S.: "Increasing the serum persistence of an IgG fragment by random mutagenesis", NAT. BIOTECHNOL., vol. 15, no. 7, 1997, pages 637 - 40 |
GOBBURU J. V.; TENHOOR C.; ROGGE M. C.; FRAZIER D. E. JR.; THOMAS D.; BENJAMIN C.; HESS D. M.; JUSKO W. J.: "Pharmacokinetics/dynamics of 5c8, a monoclonal antibody to CD154 (CD40 ligand) suppression of an immune response in monkeys", J. PHARMACOL. EXP. THER., vol. 286, no. 2, 1998, pages 925 - 30 |
GODING: "Monoclonal Antibodies: Principles and Practice", 1986, ACADEMIC PRESS, pages: 59 - 103 |
GRAVES S. S.; GOSHORN S. C.; STONE D. M.; AXWORTHY D. B.; RENO J. M.; BOTTINO B.; SEARLE S.; HENRY A.; PEDERSEN J.; REES A. R.: "Molecular modeling and preclinical evaluation of the humanized NR-LU-13 antibody", CLIN. CANCER RES., vol. 5, no. 4, 1999, pages 899 - 908 |
GRIFFITHS ET AL., EMBO J., vol. 13, 1994, pages 3245 - 60 |
HE X. Y.; XU Z.; MELROSE J.; MULLOWNEY A.; VASQUEZ M.; QUEEN C.; VEXLER V.; KLINGBEIL C.; CO M. S.; BERG E. L.: "Humanization and pharmacokinetics of a monoclonal antibody with specificity for both E- and P-selectin", J. IMMUNOL., vol. 160, no. 2, 1998, pages 1029 - 35 |
HINTON P. R.; XIONG J. M.; JOHLFS M. G.; TANG M. T.; KELLER S.; TSURUSHITA N.: "An engineered human IgG1 antibody with longer serum half-life", J. IMMUNOL., vol. 176, no. 1, 2006, pages 346 - 56 |
J. EXP. MED., vol. 108, 1995, pages 945 |
JANICE M. REICHERT; CLARK J. ROSENSWEIG; LAURA B. FADEN; MATTHEW C. DEWITZ: "Monoclonal antibody successes in the clinic", NATURE BIOTECHNOLOGY, vol. 23, 2005, pages 1073 - 8 |
JANICE M. REICHERT; VIIA E. VALGE-ARCHER: "Development trends for monoclonal antibody cancer therapeutics", NAT. REV. DRUG DISC., vol. 6, 2007, pages 349 - 356 |
K. SATO ET AL., CANCER RES., vol. 53, 1993, pages 851 - 856 |
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1987, NATIONAL INSTITUTE OF HEALTH |
KASHMIRI S. V.; SHU L.; PADLAN E. A.; MILENIC D. E.; SCHLOM J.; HAND P. H.: "Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49", HYBRIDOMA, vol. 14, no. 5, 1995, pages 461 - 73 |
KATAYOSE Y.; KUDO T.; SUZUKI M.; SHINODA M.; SAIJYO S.; SAKURAI N.; SAEKI H.; FUKUHARA K.; IMAI K.; MATSUNO S.: "MUCl-specific targeting immunotherapy with bispecific antibodies: inhibition of xenografted human bile duct carcinoma growth", CANCER RES., vol. 56, no. 18, 1996, pages 4205 - 12 |
KIM S. J.; PARK Y.; HONG H. J.: "Antibody engineering for the development of therapeutic antibodies", MOL. CELLS, vol. 20, no. 1, 2005, pages 17 - 29 |
KUNKEL, PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 488 |
LINKSOBER RJ; RADU CG; GHETIE V; WARD ES: "Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies", INT IMMUNOL., vol. 13, no. 12, 2001, pages 1551 - 9 |
LOBO E. D.; HANSEN R. J.; BALTHASAR J. P: "Antibody pharmacokinetics and pharmacodynamics", J. PHARM. SCI., vol. 93, no. 11, 2004, pages 2645 - 68 |
MA ET AL., EUR. J. IMMUNOL., vol. 24, 1994, pages 131 - 8 |
MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 97 |
MENDEZ ET AL., NAT. GENET., vol. 15, 1997, pages 146 - 56 |
MOL. CELL BIOL., vol. 8, 1988, pages 466 - 472 |
NATURE BIOTECHNOLOGY, vol. 24, 2006, pages 1591 - 7 |
NATURE BIOTECHNOLOGY, vol. 24, 2006, pages 210 - 5 |
ONO K.; OHTOMO T.; YOSHIDA K.; YOSHIMURA Y.; KAWAI S.; KOISHIHARA Y.; OZAKI S.; KOSAKA M.; TSUCHIYA M.: "The humanized anti-HM1.24 antibody effectively kills multiple myeloma cells by human effector cell-mediated cytotoxicity", MOL. IMMUNOL., vol. 36, no. 6, 1999, pages 387 - 395 |
PARDRIDGE W. M.; BUCIAK J.; YANG J.; WU D.: "Enhanced endocytosis in cultured human breast carcinoma cells and in vivo biodistribution in rats of a humanized monoclonal antibody after cationization of the protein", J PHARMACOL EXP THER., vol. 286, no. 1, 1998, pages 548 - 54 |
PAVLOU A. K.; BELSEY M. J.: "The therapeutic antibodies market to 2008", EUR. J. PHARM. BIOPHARM., vol. 59, no. 3, 2005, pages 389 - 96 |
PODUSLO J. F.; CURRAN G. L.: "Polyamine modification increases the permeability of proteins at the blood-nerve and blood-brain barriers", NEUROCHEM, vol. 66, no. 4, 1996, pages 1599 - 609 |
POPO H., BIOCHEMICAL GENETICS, vol. 28, 1990, pages 299 - 308 |
RAJPAL A.; BEYAZ N.; HABER L.; CAPPUCCILLI G.; YEE H.; BHATT R. R.; TAKEUCHI T.; LERNER R. A.; CREA R.: "A general method for greatly improving the affinity of antibodies by using combinatorial libraries", PROC. NATL. ACAD. SCI. USA, vol. 102, no. 24, 2005, pages 8466 - 71 |
RODOLFO ET AL., IMMUNOLOGY LETTERS, 1999, pages 47 - 52 |
SATO ET AL., CANCER RES., vol. 53, 1993, pages 851 - 6 |
SCHENK B. ET AL., THE JOURNAL OF CLINICAL INVESTIGATION, vol. 108, no. 11, 2001, pages 1687 - 95 |
See also references of EP2196541A4 |
SUSUMU ET AL., NATURE, vol. 315, 1985, pages 592 - 4 |
TSURUSHITA N.; HINTON P. R.; KUMAR S.: "Design of humanized antibodies: from anti-Tac to Zenapax", METHODS, vol. 36, no. 1, 2005, pages 69 - 83 |
VAISITTI T.; DEAGLIO S.; MALAVASI F.: "Cationization of monoclonal antibodies: another step towards the "magic bullet"", J. BIOL. REGUL HOMOEST. AGENTS, vol. 19, no. 3-4, 2005, pages 105 - 12 |
VALLE ET AL., NATURE, vol. 291, 1981, pages 338 - 340 |
VAUGHAN ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 309 - 14 |
WATERHOUSES ET AL., NUCLEIC ACIDS RES., vol. 21, 1993, pages 2265 - 6 |
WEITZHANDLER M. ET AL., JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 83, no. 12, 1994, pages 1670 - 5 |
YAGI T., PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 9918 - 22 |
YAMASAKI Y.; SUMIMOTO K.; NISHIKAWA M.; YAMASHITA F.; YAMAOKA K.; HASHIDA M.; TAKAKURA Y.: "Pharmacokinetic analysis of in vivo disposition of succinylated proteins targeted to liver nonparenchymal cells via scavenger receptors: importance of molecular size and negative charge density for in vivo recognition by receptors", PHARMACOL. EXP. THER., vol. 301, no. 2, 2002, pages 467 - 77 |
ZUCKIER L. S.; CHANG C. J.; SCHARFF M. D.; MORRISON S. L.: "Chimeric human-mouse IgG antibodies with shuffled constant region exons demonstrate that multiple domains contribute to in vivo half-life", CANCER RES., vol. 58, no. 17, 1998, pages 3905 - 8 |
Cited By (108)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11168344B2 (en) | 2005-03-31 | 2021-11-09 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
US10011858B2 (en) | 2005-03-31 | 2018-07-03 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
US10118959B2 (en) | 2005-10-14 | 2018-11-06 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican-3 antibody |
US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
US9670269B2 (en) | 2006-03-31 | 2017-06-06 | Chugai Seiyaku Kabushiki Kaisha | Methods of modifying antibodies for purification of bispecific antibodies |
US10934344B2 (en) | 2006-03-31 | 2021-03-02 | Chugai Seiyaku Kabushiki Kaisha | Methods of modifying antibodies for purification of bispecific antibodies |
US9688762B2 (en) | 2007-09-26 | 2017-06-27 | Chugai Sciyaku Kabushiki Kaisha | Modified antibody constant region |
US11248053B2 (en) | 2007-09-26 | 2022-02-15 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
US11332533B2 (en) | 2007-09-26 | 2022-05-17 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant region |
US9828429B2 (en) | 2007-09-26 | 2017-11-28 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
WO2009077569A1 (en) * | 2007-12-19 | 2009-06-25 | General Electric Company | Biokinetics of fast-clearing polypeptides |
US8124725B2 (en) | 2007-12-19 | 2012-02-28 | General Electric Company | PDGF-Rβ binders |
US8937047B2 (en) | 2007-12-19 | 2015-01-20 | General Electric Company | Biokinetics of fast-clearing polypeptides |
US20110104157A1 (en) * | 2008-04-04 | 2011-05-05 | Chugai Seiyaku Kabushiki Kaisha | Liver cancer drug |
US11359194B2 (en) | 2008-04-11 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding two or more antigen molecules repeatedly |
US11371039B2 (en) | 2008-04-11 | 2022-06-28 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
US9868948B2 (en) | 2008-04-11 | 2018-01-16 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
US9890377B2 (en) | 2008-04-11 | 2018-02-13 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
US10472623B2 (en) | 2008-04-11 | 2019-11-12 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding two or more antigen molecules repeatedly |
US10662245B2 (en) | 2008-09-26 | 2020-05-26 | Chugai Seiyaku Kabushiki Kaisha | Methods of reducing IL-6 activity for disease treatment |
US9228017B2 (en) | 2009-03-19 | 2016-01-05 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
US10253091B2 (en) | 2009-03-19 | 2019-04-09 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
US10066018B2 (en) | 2009-03-19 | 2018-09-04 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
EP2467400B1 (en) | 2009-08-21 | 2018-01-24 | Lonza Biologics plc. | Variant immunoglobulins with improved manufacturability |
US10150808B2 (en) | 2009-09-24 | 2018-12-11 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant regions |
JP5889181B2 (ja) * | 2010-03-04 | 2016-03-22 | 中外製薬株式会社 | 抗体定常領域改変体 |
JPWO2011108714A1 (ja) * | 2010-03-04 | 2013-06-27 | 中外製薬株式会社 | 抗体定常領域改変体 |
US10435458B2 (en) | 2010-03-04 | 2019-10-08 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variants with reduced Fcgammar binding |
JP2013539361A (ja) * | 2010-07-29 | 2013-10-24 | ゼンコア インコーポレイテッド | 改変された等電点を有する抗体 |
US11891434B2 (en) | 2010-11-30 | 2024-02-06 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
JP7096863B2 (ja) | 2010-11-30 | 2022-07-06 | 中外製薬株式会社 | 複数分子の抗原に繰り返し結合する抗原結合分子 |
JP2022105222A (ja) * | 2010-11-30 | 2022-07-12 | 中外製薬株式会社 | 複数分子の抗原に繰り返し結合する抗原結合分子 |
JPWO2012073992A1 (ja) * | 2010-11-30 | 2014-05-19 | 中外製薬株式会社 | 複数分子の抗原に繰り返し結合する抗原結合分子 |
JP6030452B2 (ja) * | 2010-11-30 | 2016-11-24 | 中外製薬株式会社 | 複数分子の抗原に繰り返し結合する抗原結合分子 |
JP2020189850A (ja) * | 2010-11-30 | 2020-11-26 | 中外製薬株式会社 | 複数分子の抗原に繰り返し結合する抗原結合分子 |
JP2017019773A (ja) * | 2010-11-30 | 2017-01-26 | 中外製薬株式会社 | 複数分子の抗原に繰り返し結合する抗原結合分子 |
JP2019048842A (ja) * | 2010-11-30 | 2019-03-28 | 中外製薬株式会社 | 複数分子の抗原に繰り返し結合する抗原結合分子 |
JP7497388B2 (ja) | 2010-11-30 | 2024-06-10 | 中外製薬株式会社 | 複数分子の抗原に繰り返し結合する抗原結合分子 |
US10618965B2 (en) | 2011-02-25 | 2020-04-14 | Chugai Seiyaku Kabushiki Kaisha | Method for altering plasma retention and immunogenicity of antigen-binding molecule |
EP3604330A1 (en) | 2011-02-25 | 2020-02-05 | Chugai Seiyaku Kabushiki Kaisha | Fcgammariib-specific fc antibody |
US11718678B2 (en) | 2011-02-25 | 2023-08-08 | Chugai Seiyaku Kabushiki Kaisha | Method for altering plasma retention and immunogenicity of antigen-binding molecule |
WO2012115241A1 (ja) | 2011-02-25 | 2012-08-30 | 中外製薬株式会社 | FcγRIIb特異的Fc抗体 |
KR20220075441A (ko) * | 2011-03-30 | 2022-06-08 | 추가이 세이야쿠 가부시키가이샤 | 항원 결합 분자의 혈장 체류성과 면역원성을 개변하는 방법 |
KR20140015501A (ko) * | 2011-03-30 | 2014-02-06 | 추가이 세이야쿠 가부시키가이샤 | 항원 결합 분자의 혈장 체류성과 면역원성을 개변하는 방법 |
WO2012133782A1 (ja) | 2011-03-30 | 2012-10-04 | 中外製薬株式会社 | 抗原結合分子の血漿中滞留性と免疫原性を改変する方法 |
KR102639563B1 (ko) | 2011-03-30 | 2024-02-21 | 추가이 세이야쿠 가부시키가이샤 | 항원 결합 분자의 혈장 체류성과 면역원성을 개변하는 방법 |
KR102403848B1 (ko) | 2011-03-30 | 2022-05-30 | 추가이 세이야쿠 가부시키가이샤 | 항원 결합 분자의 혈장 체류성과 면역원성을 개변하는 방법 |
EP3825325A2 (en) | 2011-03-30 | 2021-05-26 | Chugai Seiyaku Kabushiki Kaisha | Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity |
KR20200121900A (ko) * | 2011-03-30 | 2020-10-26 | 추가이 세이야쿠 가부시키가이샤 | 항원 결합 분자의 혈장 체류성과 면역원성을 개변하는 방법 |
KR102168731B1 (ko) | 2011-03-30 | 2020-10-23 | 추가이 세이야쿠 가부시키가이샤 | 항원 결합 분자의 혈장 체류성과 면역원성을 개변하는 방법 |
EP4011913A1 (en) | 2011-06-30 | 2022-06-15 | Chugai Seiyaku Kabushiki Kaisha | Heterodimerized polypeptide |
WO2013002362A1 (ja) | 2011-06-30 | 2013-01-03 | 中外製薬株式会社 | ヘテロ二量化ポリペプチド |
US9890218B2 (en) | 2011-06-30 | 2018-02-13 | Chugai Seiyaku Kabushiki Kaisha | Heterodimerized polypeptide |
KR20140041787A (ko) | 2011-06-30 | 2014-04-04 | 추가이 세이야쿠 가부시키가이샤 | 헤테로이량화 폴리펩티드 |
US11827699B2 (en) | 2011-09-30 | 2023-11-28 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing antibodies promoting disappearance of antigens having plurality of biological activities |
US10253100B2 (en) | 2011-09-30 | 2019-04-09 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance |
US11820793B2 (en) | 2011-11-30 | 2023-11-21 | Chugai Seiyaku Kabushiki Kaisha | Drug containing carrier into cell for forming immune complex |
WO2013100120A1 (ja) | 2011-12-28 | 2013-07-04 | 中外製薬株式会社 | ヒト化抗Epiregulin抗体および当該抗体を有効成分として含む癌治療剤 |
WO2013187495A1 (ja) | 2012-06-14 | 2013-12-19 | 中外製薬株式会社 | 改変されたFc領域を含む抗原結合分子 |
US11142563B2 (en) | 2012-06-14 | 2021-10-12 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule containing modified Fc region |
EP4310191A2 (en) | 2012-06-14 | 2024-01-24 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule containing modified fc region |
US10919953B2 (en) | 2012-08-24 | 2021-02-16 | Chugai Seiyaku Kabushiki Kaisha | FcgammaRIIB-specific Fc region variant |
EP3721900A1 (en) | 2012-08-24 | 2020-10-14 | Chugai Seiyaku Kabushiki Kaisha | Fcgammariib-specific fc region variant |
WO2014030728A1 (ja) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | FcγRIIb特異的Fc領域改変体 |
EP3557260A1 (en) | 2012-12-21 | 2019-10-23 | Chugai Seiyaku Kabushiki Kaisha | Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy |
US10451627B2 (en) | 2012-12-21 | 2019-10-22 | Chugai Seiyaku Kabushiki Kaisha | Method for assaying soluble GPC3 protein |
WO2014097648A1 (ja) | 2012-12-21 | 2014-06-26 | 中外製薬株式会社 | Gpc3標的治療剤療法が有効である患者に投与されるgpc3標的治療剤 |
EP4119947A1 (en) | 2012-12-21 | 2023-01-18 | Chugai Seiyaku Kabushiki Kaisha | Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy |
US10782300B2 (en) | 2012-12-21 | 2020-09-22 | Chugai Seiyaku Kabushiki Kaisha | GPC3-targeting drug which is administered to patient responsive to GPC3-targeting drug therapy |
KR20150097786A (ko) | 2012-12-27 | 2015-08-26 | 추가이 세이야쿠 가부시키가이샤 | 헤테로이량화 폴리펩티드 |
US10766960B2 (en) | 2012-12-27 | 2020-09-08 | Chugai Seiyaku Kabushiki Kaisha | Heterodimerized polypeptide |
WO2014104165A1 (ja) | 2012-12-27 | 2014-07-03 | 中外製薬株式会社 | ヘテロ二量化ポリペプチド |
US11267868B2 (en) | 2013-04-02 | 2022-03-08 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
WO2014208482A1 (ja) | 2013-06-24 | 2014-12-31 | 中外製薬株式会社 | ヒト化抗Epiregulin抗体を有効成分として含む腺癌以外の非小細胞肺癌の治療剤 |
US11124576B2 (en) | 2013-09-27 | 2021-09-21 | Chungai Seiyaku Kabushiki Kaisha | Method for producing polypeptide heteromultimer |
US11760807B2 (en) | 2014-05-08 | 2023-09-19 | Chugai Seiyaku Kabushiki Kaisha | GPC3-targeting drug which is administered to patient responsive to GPC3-targeting drug therapy |
KR20170003972A (ko) | 2014-05-08 | 2017-01-10 | 추가이 세이야쿠 가부시키가이샤 | Gpc3 표적 치료제 요법이 유효한 환자에게 투여되는 gpc3 표적 치료제 |
US9975966B2 (en) | 2014-09-26 | 2018-05-22 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing theraputic agent |
US11001643B2 (en) | 2014-09-26 | 2021-05-11 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
US11352440B2 (en) | 2014-11-21 | 2022-06-07 | Bristol-Myers Squibb Company | Antibodies against CD73 and uses thereof |
US9765135B2 (en) | 2014-12-19 | 2017-09-19 | Chugai Seiyaku Kabushiki Kaisha | Anti-C5 antibodies |
US10385122B2 (en) | 2014-12-19 | 2019-08-20 | Chugai Seiyaku Kabushiki Kaisha | Nucleic acids encoding anti-C5 antibodies |
US10000560B2 (en) | 2014-12-19 | 2018-06-19 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use |
US11597760B2 (en) | 2014-12-19 | 2023-03-07 | Chugai Seiyaku Kabushiki Kaisha | Method of detecting the presence of complement C5 |
WO2016098357A1 (en) | 2014-12-19 | 2016-06-23 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
US10023630B2 (en) | 2014-12-19 | 2018-07-17 | Chugai Seiyaku Kabushiki Kaisha | Methods of neutralizing C5 with anti-C5 antibodies |
US11454633B2 (en) | 2014-12-19 | 2022-09-27 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use |
US10738111B2 (en) | 2014-12-19 | 2020-08-11 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use |
US10519229B2 (en) | 2015-02-05 | 2019-12-31 | Chugai Seiyaku Kabushiki Kaisha | Nucleic acids encoding IL-8 antibodies |
US9969800B2 (en) | 2015-02-05 | 2018-05-15 | Chugai Seiyaku Kabushiki Kaisha | IL-8 antibodies |
US11180548B2 (en) | 2015-02-05 | 2021-11-23 | Chugai Seiyaku Kabushiki Kaisha | Methods of neutralizing IL-8 biological activity |
US10774148B2 (en) | 2015-02-27 | 2020-09-15 | Chugai Seiyaku Kabushiki Kaisha | Composition for treating IL-6-related diseases |
US11142587B2 (en) | 2015-04-01 | 2021-10-12 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide hetero-oligomer |
US11376326B2 (en) | 2015-07-01 | 2022-07-05 | Chugai Seiyaku Kabushiki Kaisha | GPC3-targeting therapeutic agent which is administered to patient for whom the GPC3-targeting therapeutic agent is effective |
US11359009B2 (en) | 2015-12-25 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
US11649262B2 (en) | 2015-12-28 | 2023-05-16 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of Fc region-containing polypeptide |
EP4112641A1 (en) | 2016-03-15 | 2023-01-04 | Chugai Seiyaku Kabushiki Kaisha | Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies |
US11767362B1 (en) | 2016-03-15 | 2023-09-26 | Chugai Seiyaku Kabushiki Kaisha | Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies |
WO2017159699A1 (en) | 2016-03-15 | 2017-09-21 | Chugai Seiyaku Kabushiki Kaisha | Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies |
US11780912B2 (en) | 2016-08-05 | 2023-10-10 | Chugai Seiyaku Kabushiki Kaisha | Composition for prophylaxis or treatment of IL-8 related diseases |
US11053308B2 (en) | 2016-08-05 | 2021-07-06 | Chugai Seiyaku Kabushiki Kaisha | Method for treating IL-8-related diseases |
WO2018038046A1 (ja) | 2016-08-22 | 2018-03-01 | 中外製薬株式会社 | ヒトgpc3ポリペプチドを発現する遺伝子改変非ヒト動物 |
US11608374B2 (en) | 2017-01-30 | 2023-03-21 | Chugai Seiyaku Kabushiki Kaisha | Anti-sclerostin antibodies and methods of use |
WO2018155611A1 (ja) | 2017-02-24 | 2018-08-30 | 中外製薬株式会社 | 薬学的組成物、抗原結合分子、治療方法、およびスクリーニング方法 |
US11851486B2 (en) | 2017-05-02 | 2023-12-26 | National Center Of Neurology And Psychiatry | Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils |
WO2019059411A1 (en) | 2017-09-20 | 2019-03-28 | Chugai Seiyaku Kabushiki Kaisha | DOSAGE FOR POLYTHERAPY USING PD-1 AXIS BINDING ANTAGONISTS AND GPC3 TARGETING AGENT |
WO2023091909A1 (en) | 2021-11-16 | 2023-05-25 | Sotio Biotech Inc. | Treatment of myxoid/round cell liposarcoma patients |
WO2024038144A1 (en) | 2022-08-18 | 2024-02-22 | Tribune Therapeutics Ab | Agents that inhibit ccn ligand-induced signalling for treating disease |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009041062A1 (ja) | 血漿中動態が改善されたグリピカン3抗体 | |
WO2009041643A1 (ja) | Cdrのアミノ酸置換により抗体の等電点を改変する方法 | |
NZ597260A (en) | Formulations for parenteral delivery of compounds and uses thereof comprising methylnaltrexone | |
WO2008003958A3 (en) | Fused pyrimido compounds | |
WO2008045563A3 (en) | Modification of ionic strength in antibody-solutions to reduce opalescence/aggregates | |
EP2054042B8 (en) | Methods for the preparation of biologically active compounds in nanoparticulate form | |
UA97351C2 (ru) | Производная кумарина, имеющая противоопухолевую активность | |
WO2006128764A3 (en) | Process for cultivating animal cells comprising the feeding of plant-derived peptones | |
WO2008062376A3 (en) | New process for the preparation of 2-imino-thiazolidin-4-one derivatives | |
GEP20156328B (en) | Solid pharmaceutical compositions and processes for their production | |
AU2003221604A1 (en) | Use of an active substance that binds to cd28 for producing a pharmaceutical composition | |
WO2008082508A3 (en) | Process for the preparation of 6,6-dimethyl-3-azabicyclo- [3.1.0]- hexane compounds utilizing bisulfite intermediate | |
MX2012007590A (es) | Composicion para mejorar la funcion cerebral y metodo para mejorar la funcion cerebral. | |
WO2008019782A3 (de) | Dispersionen von nanoharnstoffen. enthaltend wirkstoffe | |
WO2009057136A3 (en) | Epimerization by stereoselective synthesis of vitamin d analogues | |
WO2012148148A3 (en) | Novel zinc azide complex and a process for preparing tetrazole derivatives using the same | |
AU2003279570A1 (en) | Delivery agent, method of delivering a target substance to cells, method for producing delivery agent, composition for producing delivery agent, and kit for producing delivery agent | |
WO2009011449A3 (en) | Pharmaceutical composition comprising 11-deoxy-prostaglandin compound and method for stabilizing the compound | |
MY152388A (en) | Composition and method for controlling plant diseases | |
WO2008057464A3 (en) | Compositions and methods for improving the bioavailability of liothyronine | |
WO2008090533A3 (en) | A bone cement | |
WO2007015918A3 (en) | Novel biologically active peptides and their new uses | |
WO2011031099A3 (en) | Ursodeoxycholic acid-synthetic hydrotalcite-eudragit hybrid, pharmaceutical composition containing the same and method for preparing the same | |
SI2200981T1 (sl) | Novi derivati karbamoilglicina | |
WO2009011420A1 (ja) | 2型糖尿病の治療薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880109196.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08834671 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009534190 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2010/003158 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2700986 Country of ref document: CA Ref document number: 204754 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12010500666 Country of ref document: PH Ref document number: 2008834671 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010030499 Country of ref document: EG |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10041193 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201011369 Country of ref document: CR Ref document number: CR2010-011369 Country of ref document: CR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 584769 Country of ref document: NZ Ref document number: 2008305851 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2357/CHENP/2010 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 20107008895 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201005066 Country of ref document: UA Ref document number: 2010116756 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: PI 2010001360 Country of ref document: MY |
|
ENP | Entry into the national phase |
Ref document number: 2008305851 Country of ref document: AU Date of ref document: 20080926 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12733933 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: PI0817637 Country of ref document: BR Free format text: COM BASE NA RESOLUCAO 228/09, SOLICITA-SE QUE SEJAM APRESENTADOS NOVOS CDS/DVDS E RESPECTIVOS CODIGOS ALFANUMERICOS E DECLARACOES, POIS O TITULO DA LISTAGEM DE SEQUENCIA NAO ESTA EM LINGUA VERNACULA. |
|
ENP | Entry into the national phase |
Ref document number: PI0817637 Country of ref document: BR Kind code of ref document: A2 Effective date: 20100329 |